...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of International Medical Research >Evaluation of Guanabenz Added to Hydrochlorothiazide Therapy in Hypertension
【24h】

Evaluation of Guanabenz Added to Hydrochlorothiazide Therapy in Hypertension

机译：盐酸加氢氯噻嗪治疗中加用瓜纳本斯的评估

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Guanabenz, a centrally acting a-adrenergic antihypertensive agent, produces neither the sodium retention seen with other centrally acting agents nor the metabolic abnormalities characteristic of diuretics. In this study, which involved 204 hypertensive out-patients, the additive effects of guanabenz and hydrochlorothiazide were compared with the effects of hydrochlorothiazide therapy alone. Before randomization to the 6-month blinded addition of either guanabenz or placebo, hydrochlorothiazide (50 or 100 mg/day; mean, 70 mg/day) was administered as sole therapy for 6 weeks. During this time, mean supine diastolic blood pressure (SDBP) decreased from 102 to 94 mm Hg (p < 0·01), with a satisfactory clinical response rate of 62% and a mean weight loss of 2 lbs (p < 0·01). No further change in mean SDBP occurred during the next 6 months of diuretic therapy, whereas the addition of guanabenz (mean dose, 24 mg/day) caused a further decrease in mean SDBP to 88 mm Hg (p < 0·01), an increase in the response rate to 86%, and no weight change. Pulse rates in both groups were unchanged. The principal side-effects in both groups were dry mouth, drowsiness, weakness, and dizziness, with a greater incidence of each during the combination therapy. The usual laboratory abnormalities were associated with hydrochlorothiazide. Guanabenz was found to enhance the antihypertensive efficacy of hydrochlorothiazide without compromising its natriuretic properties or producing additional metabolic abnormalities.
机译：瓜纳本斯是一种中枢性α-肾上腺素能降压药，既不会产生其他中枢性药剂所见的钠retention留，也不会产生利尿剂的代谢异常。在这项涉及204位高血压门诊患者的研究中，将胍阿宾斯和氢氯噻嗪的累加作用与单独使用氢氯噻嗪治疗的作用进行了比较。在随机分配至6个月不加用胍阿宾斯或安慰剂的随机分组之前，氢氯噻嗪（50或100毫克/天;平均为70毫克/天）作为唯一疗法服用了6周。在此期间，平均仰卧舒张压（SDBP）从102毫米汞柱降至94毫米汞柱（p <0·01），令人满意的临床缓解率为62％，平均体重减轻了2 lbs（p <0· 01）。在接下来的6个月利尿剂治疗中，平均SDBP没有进一步变化，而添加胍贝芬（平均剂量，每天24 mg）导致平均SDBP进一步降低至88 mm Hg（p <0·01），响应率提高到86％，并且体重没有变化。两组的脉搏率均未改变。两组的主要副作用是口干，嗜睡，虚弱和头晕，在联合治疗期间每种药物的发生率均较高。通常的实验室异常与氢氯噻嗪有关。瓜纳宾斯被发现可以增强氢氯噻嗪的抗高血压功效，而不损害其利尿钠性质或产生其他代谢异常。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号